Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19

Am J Respir Crit Care Med. 2020 Dec 15;202(12):1733-1734. doi: 10.1164/rccm.202007-2913LE.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / therapeutic use
  • COVID-19*
  • Drug Monitoring
  • Humans
  • SARS-CoV-2
  • Venous Thromboembolism*

Substances

  • Anticoagulants